The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

Suda, Goki; Nakai, Masato; Sho, Takuya; Kimura, Megumi; Shimazaki, Tomoe; Maehara, Osamu; Shigesawa, Taku; Suzuki, Kazuharu; Nakamura, Akihisa; Ohara, Masatsugu; Umemura, Machiko; Kawagishi, Naoki; Baba, Masaru; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Sakamoto, Naoya

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment

Suda, Goki; Nakai, Masato; Sho, Takuya et al.

Internal medicine, 2019, 58(7), 943-947

Permalink : https://hdl.handle.net/2115/74043

このアイテムのアクセス数:808件（2026-08-19 05:24 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
58_2077-18	pdf	197 KB	294

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/74043
タイトル	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
著者	Suda, Goki ; Nakai, Masato ; Sho, Takuya ; Kimura, Megumi ; Shimazaki, Tomoe ; Maehara, Osamu ; Shigesawa, Taku ; Suzuki, Kazuharu ; Nakamura, Akihisa ; Ohara, Masatsugu ; Umemura, Machiko ; Kawagishi, Naoki ; Baba, Masaru ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Sakamoto, Naoya
e-Rad_Researcher 20447460 著者名 Suda, Goki
著者名 Nakai, Masato
著者名 Sho, Takuya
著者名 Kimura, Megumi
著者名 Shimazaki, Tomoe
著者名 Maehara, Osamu
著者名 Shigesawa, Taku
著者名 Suzuki, Kazuharu
著者名 Nakamura, Akihisa
著者名 Ohara, Masatsugu
著者名 Umemura, Machiko
著者名 Kawagishi, Naoki
著者名 Baba, Masaru
e-Rad_Researcher 80642446 著者名 Natsuizaka, Mitsuteru
著者名 Morikawa, Kenichi
e-Rad_Researcher 20735188 著者名 Ogawa, Koji
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
キーワード	HCV
	retreatment
	glecaprevir
	pibrentasvir
	hemodialysis
発行日	2019-04-01
出版者	日本内科学会
出版者	The Japanese Society of Internal Medicine
収録物名	Internal medicine
巻(号)	58(7)
ページ	943-947
抄録	Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir).
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
PISSN	0918-2918
関連情報	PMID 30568153
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.2169/internalmedicine.2077-18